Cargando…

Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors

Effective treatments for brain tumors remain one of the most urgent and unmet needs in modern oncology. This is due not only to the presence of the neurovascular unit/blood–brain barrier (NVU/BBB) but also to the heterogeneity of barrier alteration in the case of brain tumors, which results in what...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffith, Jessica I., Rathi, Sneha, Zhang, Wenqiu, Zhang, Wenjuan, Drewes, Lester R., Sarkaria, Jann N., Elmquist, William F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763839/
https://www.ncbi.nlm.nih.gov/pubmed/33322488
http://dx.doi.org/10.3390/pharmaceutics12121205
_version_ 1783628113620500480
author Griffith, Jessica I.
Rathi, Sneha
Zhang, Wenqiu
Zhang, Wenjuan
Drewes, Lester R.
Sarkaria, Jann N.
Elmquist, William F.
author_facet Griffith, Jessica I.
Rathi, Sneha
Zhang, Wenqiu
Zhang, Wenjuan
Drewes, Lester R.
Sarkaria, Jann N.
Elmquist, William F.
author_sort Griffith, Jessica I.
collection PubMed
description Effective treatments for brain tumors remain one of the most urgent and unmet needs in modern oncology. This is due not only to the presence of the neurovascular unit/blood–brain barrier (NVU/BBB) but also to the heterogeneity of barrier alteration in the case of brain tumors, which results in what is referred to as the blood–tumor barrier (BTB). Herein, we discuss this heterogeneity, how it contributes to the failure of novel pharmaceutical treatment strategies, and why a “whole brain” approach to the treatment of brain tumors might be beneficial. We discuss various methods by which these obstacles might be overcome and assess how these strategies are progressing in the clinic. We believe that by approaching brain tumor treatment from this perspective, a new paradigm for drug delivery to brain tumors might be established.
format Online
Article
Text
id pubmed-7763839
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77638392020-12-27 Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors Griffith, Jessica I. Rathi, Sneha Zhang, Wenqiu Zhang, Wenjuan Drewes, Lester R. Sarkaria, Jann N. Elmquist, William F. Pharmaceutics Review Effective treatments for brain tumors remain one of the most urgent and unmet needs in modern oncology. This is due not only to the presence of the neurovascular unit/blood–brain barrier (NVU/BBB) but also to the heterogeneity of barrier alteration in the case of brain tumors, which results in what is referred to as the blood–tumor barrier (BTB). Herein, we discuss this heterogeneity, how it contributes to the failure of novel pharmaceutical treatment strategies, and why a “whole brain” approach to the treatment of brain tumors might be beneficial. We discuss various methods by which these obstacles might be overcome and assess how these strategies are progressing in the clinic. We believe that by approaching brain tumor treatment from this perspective, a new paradigm for drug delivery to brain tumors might be established. MDPI 2020-12-11 /pmc/articles/PMC7763839/ /pubmed/33322488 http://dx.doi.org/10.3390/pharmaceutics12121205 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Griffith, Jessica I.
Rathi, Sneha
Zhang, Wenqiu
Zhang, Wenjuan
Drewes, Lester R.
Sarkaria, Jann N.
Elmquist, William F.
Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
title Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
title_full Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
title_fullStr Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
title_full_unstemmed Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
title_short Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
title_sort addressing bbb heterogeneity: a new paradigm for drug delivery to brain tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763839/
https://www.ncbi.nlm.nih.gov/pubmed/33322488
http://dx.doi.org/10.3390/pharmaceutics12121205
work_keys_str_mv AT griffithjessicai addressingbbbheterogeneityanewparadigmfordrugdeliverytobraintumors
AT rathisneha addressingbbbheterogeneityanewparadigmfordrugdeliverytobraintumors
AT zhangwenqiu addressingbbbheterogeneityanewparadigmfordrugdeliverytobraintumors
AT zhangwenjuan addressingbbbheterogeneityanewparadigmfordrugdeliverytobraintumors
AT dreweslesterr addressingbbbheterogeneityanewparadigmfordrugdeliverytobraintumors
AT sarkariajannn addressingbbbheterogeneityanewparadigmfordrugdeliverytobraintumors
AT elmquistwilliamf addressingbbbheterogeneityanewparadigmfordrugdeliverytobraintumors